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Abstract 
      
  Gliomas, which are brain tumors that arise from glial cells, are some of 
the most aggressive and lethal types of tumors. These brain tumors are 
difficult to treat because not enough information regarding the mutations 
present in these tumors exists. This project studies effects of a p53 
mutation on Drosophila glioma progression and then will test to see if this 
results in resistance to current chemotherapy. Drosophila are used as 
model organisms to mimic these processes. The current genetic crosses 
that have been created will be studied, and an effective p53 knockdown 
will be made. In essence, this will effectively mimic a human brain tumor 
so the treatments tested and the data collected from this model can be 
applied to the current understanding of human gliomas. In addition to 
studying just the p53 mutation, PI3K and oncogenic Ras signaling will be 
coactivated. This will lead to an even more accurate glioma model 
because multiple mutations, such as the ones added are present in 
human tumors as well. These genetic crosses will be treated with 
Tyrosine Kinase Inhibitors, which are currently used to treat brain cancer 
patients in order to find out whether or not this mutation plays a role in 
resistance to current therapy. The main goal of this endeavor is to 
investigate the numerous defects occurring at the cellular and 
biochemical level in gliomas, which will give insight into why these types 
of tumors are so difficult to treat. Data gathered from this project will lead 
to further inquiry into the role of p53 mutations in gliomas and hopefully, 
to better outcomes for those affected by this type of cancer. Here, we 
present the data gathered from this project thus far. 
 
     The goal of this project is to investigate why some gliomas do not 
respond well to chemotherapy. One approach to this is to compare the 
response of two genetically different glioma to a sleuth of drugs known to 
partially affect or weakly inhibit tumor growth. The p53 mutation is thought 
to play a role in this resistance. This specific mutation can be modeled in 
Drosophila melanogaster, both independently and in conjunction with 
other commonly occurring mutations in glioma. 
 
     The p53 gene acts as a tumor suppressor in addition to its numerous 
other functions concerning the cell cycle. The E2F family of genes, which 
will also be tested along with p53, help control the cell cycle. Mutations in 
both of these genes are known to occur in patients with gliomas, but their 
role in glioma progression and response to therapies is not well 
understood. 
 
     If more information regarding the exact mutations present in gliomas 
existed, more targeted therapies could be used to act on the pathways 
known to contribute to tumor development and chemotherapy resistance. 
This project aims to explore these mutations in an effort to bridge this gap 
in information, so therapies can efficiently destroy the tumor without 
causing damage to healthy tissues. We present the preliminary data 
necessary to create the various glioma model here. 
Future Directions 
 
1. Create an effective glioma model expressing a p53 mutation 
2. Combine the p53 mutation with coactivation of Ras PI3 Kinase 
along with additional mutations that are present in human gliomas. 
3. Treat the p53, Ras PI3 Kinase gliomas with Tyrosine Kinase 
Inhibitors in order to test  for therapy resistance. 
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Conclusions 
Role of p53 
 
     This specific gene is known to be a tumor suppressor but it also has 
many other vital functions, such as modulating the cell cycle, repairing 
DNA and triggering apoptosis. Certain p53 mutations are thought to be 
early events in the process of tumorigenesis. Loss of p53 can cause an 
increased risk for gliomas to develop when they occur as germline 
mutations and often occur with the deletion of the chromosome 17p. 
p53 mutations are most often seen in patients with high-grade gliomas 
rather than those with low-grade tumors, which suggests its possible 
usefulness in predicting prognoses. We will use a dominant negative 
p53 mutation [UAS-p53H159N] for our studies. 
 
Role of E2F 
E2F genes encode transcription factors that are responsible for 
modulating the cell cycle. The transcription factors are known to play a 
role during the transition from the G1 to the S phase, however, they are 
thought to modulate other phases of the cycle as well. These E2F 
genes can also work as tumor suppressors and when mutations occur, 
this function no longer works correctly.  Furthermore, E2F makes 
proteins that mediate p53-independent/dependent apoptosis. We will 




• The larvae produced from the UASp53H159N; repoGal4 cross had 
decreased glia in the optic lobes and they were clustered in the 
ventral nerve cord. 
 
• The larvae produced from the UASE2FRNAi; repoGal4 cross had glia 
clustered in the ventral nerve cord as well. 
 
• Some of the larvae from the UASE2FRNAi; repoGal4 were deformed 
and had their ventral nerve cord curved upward, attached to an optic 
lobe. 
 
• A majority of the larvae hatched. This viability shows that further 
crosses made with this offspring are possible. 
 
• This data shows promise for continued genetic crosses to eventually 




Functions of p53 
Fig. 1: Loss of p53 causes reduction 
in glia 
B) repoGFP>UAS-p53H159N  
C)repoGFP>UAS-p53H159N  
A) repoGFP control B) repoGFP>UAS-E2f1RNAi  A) repoGFP control 
Fig. 2: Loss of E2F1 causes 
reduction in glia 
C) repoGFP>UAS-E2f1RNAi  
